Intra-arterial Therapy for Stroke (TESLA Trial)

N/A

Waitlist Available

Led By Albert J Yoo, MD, PhD

Research Sponsored by Mercy Health Ohio

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 90 days post randomization

Awards & highlights

TESLA Trial Summary

This trial is testing a new treatment for strokes. It will adaptively enrich to better define the upper limit of infarct volume for treatment eligibility and assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.

Who is the study for?

The TESLA Trial is for adults aged 18-85 with acute ischemic stroke, showing specific symptoms and scoring over 6 on the NIHSS. They must have a blockage in certain arteries of the brain, be able to join within 24 hours of symptom onset, and have had good health before the stroke. Pregnant women or those with severe allergies to contrast media, uncontrolled high blood pressure, certain CT scan findings that suggest risk are excluded.Check my eligibility

What is being tested?

This trial tests Intra-arterial Therapy (IAT) against standard medical management in patients with moderate to large strokes as seen on imaging. It aims to find out if IAT can help these patients recover better than usual treatments alone and identify which patient groups might benefit most from this approach.See study design

What are the potential side effects?

While not explicitly listed here, potential side effects may include reactions related to contrast media used during IAT such as nausea or rash; risks associated with endovascular procedures like bleeding or vessel damage; and typical stroke complications including weakness or speech difficulties.

TESLA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 90 days post randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~90 days post randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Utility-weighted 90-day Modified Rankin Score

TESLA Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intra-arterial TherapyExperimental Treatment1 Intervention

For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.

Group II: Medical ManagementActive Control1 Intervention

Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.

Do I qualify?Apply below to find out